CLINICAL TRIALS PROFILE FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
✉ Email this page to a colleague
All Clinical Trials for collagenase clostridium histolyticum
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00261209 ↗ | Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand | Completed | Stony Brook University | Phase 1/Phase 2 | 2005-01-01 | The purpose of this study is to dissolve flexor tendon adhesions associated with failed tendon repair surgery. |
| NCT01229436 ↗ | Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex) | Completed | Pfizer | Phase 3 | 2010-12-01 | This study will evaluate the impact of Xiapex treatment on the range of motion (ROM) of the affected fingers and the patient and physician reported treatment satisfaction and disease severity and their relation to ROM. Recovery to normal activities, recovery time (How long overall, time to use hand, time to return to work or daily activities, amount of work or daily activity time missed or reduced and affects on productivity and daily activities) will be assessed via patient diary. Use of concomitant analgesic medications will be recorded and total healthcare resource utilization (HCRU). |
| NCT01588353 ↗ | Collagenase Option for Reduction of Dupuytren's Contracture in Japan | Completed | Asahi Kasei Pharma Corporation | Phase 3 | 2012-05-01 | To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture. To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture. |
| NCT01613313 ↗ | A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma | Completed | Advance Biofactures Corporation | Phase 2 | 2012-05-01 | The purpose of this research is to evaluate the safest and most effective dose of a Food and Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors of varying sizes that occur commonly in the adult population). The fat in the lipoma is like normal fat except that it is enclosed in a balloon-like structure which is made of collagen (fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size of the lipoma or removing it. |
| NCT01613313 ↗ | A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma | Completed | Zachary Gerut | Phase 2 | 2012-05-01 | The purpose of this research is to evaluate the safest and most effective dose of a Food and Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors of varying sizes that occur commonly in the adult population). The fat in the lipoma is like normal fat except that it is enclosed in a balloon-like structure which is made of collagen (fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size of the lipoma or removing it. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for collagenase clostridium histolyticum
Condition Name
Clinical Trial Locations for collagenase clostridium histolyticum
Trials by Country
Clinical Trial Progress for collagenase clostridium histolyticum
Clinical Trial Phase
Clinical Trial Sponsors for collagenase clostridium histolyticum
Sponsor Name
